Trial
NCT06682234
Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Filovirus Disease
Intervention
obeldesivir
Why stopped
The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-20